Kimio Yonesaka

12PUBLICATIONS
41CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 12, 2026
Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer.

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 11, 2026
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Hiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi

|Jan 12, 2026
Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Kimio Yonesaka

|Dec 18, 2021
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi

|Aug 08, 2021
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura

Pageof 2

Frequent Collaborators

6 joint publications

Kazuhiko Nakagawa

5 joint publications

Hidetoshi Hayashi

5 joint publications

Hisato Kawakami

3 joint publications

Kazuto Nishio